We examined the association of biomarkers implicated in bone function and health (osteocalcin [total], CTX, sclerostin, and bicarbonate; henceforth “bone-related biomarkers”) with future hip fracture over a median follow-up of more than a decade and tested whether inclusion of these biomarkers improved fracture prediction over clinical factors alone and therefore whether they may have a role in clinical risk prediction in routine care. This evidence concerns the gene SOST and hip fracture.